指南与共识心力衰竭与心肌病

新诊断射血分数降低心衰患者指南导向药物治疗的纵向使用与强化中的性别差异

Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
指南 / 共识 · Circulation · 2024-01-23

该研究基于2016至2020年Optum数据库中新诊断的射血分数降低心衰(HFrEF)患者,评估12个月内达到最佳指南导向药物治疗(GDMT)的情况。结果显示仅6.2%的患者在12个月时达到最佳GDMT,女性相比男性在每个随访时间点使用所有GDMT类别及最佳GDMT的比例均更低,校正后女性达到最佳GDMT的概率低23%(HR 0.77,95%CI 0.71-0.83,P<0.001)。

要点

  • 新诊断HFrEF患者12个月内仅6.2%达到最佳GDMT。
  • 女性达到最佳GDMT的概率较男性低23%(HR 0.77)。
  • 性别差异在商业保险和年轻患者中更显著。

核心结论

  • 新诊断HFrEF后最佳GDMT总体使用率低,女性使用率显著低于男性。
  • 需针对性地改善GDMT的启动和滴定。

研究设计与样本

  • 回顾性队列研究,数据来自2016至2020年Optum去标识化Clinformatics Data Mart数据库,纳入新诊断HFrEF患者63 759例(平均年龄71.3岁,56.6%男性)。
  • 主要结局为HFrEF诊断后12个月内最佳GDMT的使用,采用时间-事件分析和校正Cox比例风险模型评估。

主要发现

  • 12个月时仅6.2%的患者达到最佳GDMT。
  • 女性在每个随访时间点使用所有GDMT类别及最佳GDMT的比例均低于男性。
  • 校正后女性达到最佳GDMT的概率低23%(HR 0.77,95%CI 0.71-0.83,P<0.001)。
  • 商业保险患者中性别差异更显著(女性vs男性HR 0.66,95%CI 0.58-0.76;与Medicare比较HR 0.85,95%CI 0.77-0.92;交互P=0.005)。

关键数值与推荐

  • 最佳GDMT定义为:≥50%目标剂量的循证β受体阻滞剂联合≥50%目标剂量的ACEI或ARB,或任意剂量的ARNI联合任意剂量的MRA。

临床怎么用

  • 临床实践中应关注女性HFrEF患者GDMT的启动和滴定,尤其商业保险和年轻患者。
  • 需要实施针对性措施以提高GDMT的启动和强化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guideline-directed medical therapies (GDMTs) are the mainstay of treatment for heart failure with reduced ejection fraction (HFrEF), but they are underused. Whether sex differences exist in the initiation and intensification of GDMT for newly diagnosed HFrEF is not well established. METHODS: Patients with incident HFrEF were identified from the 2016 to 2020 Optum deidentified Clinformatics Data Mart Database, which is derived from a database of administrative health claims for members of large commercial and Medicare Advantage health plans. The primary outcome was the use of optimal GDMT within 12 months of HFrEF diagnosis. Consistent with the guideline recommendations during the time period of the study, optimal GDMT was defined as ≥50% of the target dose of evidence-based beta-blocker plus ≥50% of the target dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, or any dose of angiotensin receptor neprilysin inhibitor plus any dose of mineralocorticoid receptor antagonist. The probability of achieving optimal GDMT on follow-up and predictors of optimal GDMT were evaluated with time-to-event analysis with adjusted Cox proportional hazard models. RESULTS: The study cohort included 63 759 patients (mean age, 71.3 years; 15.2% non-Hispanic Black race; 56.6% male). Optimal GDMT use was achieved by 6.2% of patients at 12 months after diagnosis. Female (compared with male) patients with HFrEF had lower use across every GDMT class and lower use of optimal GDMT at each time point at follow-up. In an adjusted Cox model, female sex was associated with a 23% lower probability of achieving optimal GDMT after diagnosis (hazard ratio [HR], 0.77 [95% CI, 0.71-0.83]; P<0.001). The sex disparities in GDMT use after HFrEF diagnosis were most pronounced among patients with commercial insurance (females compared with males; HR, 0.66 [95% CI, 0.58-0.76]) compared with Medicare (HR, 0.85 [95% CI, 0.77-0.92]); Pinteraction sex×insurance status=0.005) and for younger patients (age <65 years: HR, 0.65 [95% CI, 0.58-0.74]) compared with older patients (age ≥65 years: HR, 87 [95% CI, 80-96]) Pinteraction sex×age=0.009). CONCLUSIONS: Overall use of optimal GDMT after HFrEF diagnosis was low, with significantly lower use among female (compared with male) patients. These findings highlight the need for implementation efforts directed at improving GDMT initiation and titration.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Sumarsono, Xie, Keshvani, et al. Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction. Circulation. 2024. PMID: 38258605. doi:10.1161/CIRCULATIONAHA.123.067489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。